CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...